The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.
 
Benjamin Philip Levy
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Guardant Health; Lilly; Merck; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Turning Point Therapeutics (Inst)
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Lilly; MSD; Novocure; Pfizer; PharmaMar; Roche; Sanofi; Takeda Science Foundation
Consulting or Advisory Role - Amgen; AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Lilly; MSD; Novocure; Pfizer; Pharmamab; Roche; Sanofi; Takeda Science Foundation
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Siddhartha Rawat
Employment - Daiichi Sankyo; Merck (I)
Stock and Other Ownership Interests - Merck (I)
 
Jingdong Xie
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Priyanka Basak
Employment - United Anesthesia Services
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS